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LETTERS TO THE EDITOR
Gefitinib-Associated
Propionibacterium acnes
Pleural Empyema
To the Editor:
Inhibition of the tyrosine kinase
activity of the epithelial growth factor
receptor (EGFR) by specific inhibitors
(TKIs) resulted in a survival benefit in
patients with metastatic non-small cell
lung cancer in large placebo-controlled
phase III trials. EGFR-TKIs have now
full approval for treatment of patients
with metastatic non-small cell lung can-
cer after progression with first-line plat-
inum-based chemotherapy.1 However,
both gefitinib and erlotinib have similar
dermatologic side effects that mimic ac-
nea vulgaris and require drug with-
drawal or dose reduction in up to 9% of
cases. The role of Propionibacterium
acnes colonization in these skin lesions
is debated. Furthermore, skin lesions
may also be an important marker of
antitumor activity since they occurred
more frequently in responders than in
nonresponders, usually in the first weeks
of treatment.2 We report here a case of
an P. acnes pleural empyema associated
with severe gefitinib-induced skin toxic-
ity and repeated thoracocenteses.
A 50-year-old nonsmoker woman
underwent a right upper lobectomy for
severe hemoptysis. Primary lung adeno-
carcinoma (CK7/CK20/TTF1) was
diagnosed and staged pT2N0M0 due to
visceral pleura involvement. Four months
later, adenocarcinoma-related right pleural
effusion was treated by a platinum/gem-
citabine doublet and pleurodesis, followed
by second-line docetaxel therapy given
because of progressive disease. Thoraco-
centesis was performed once. With further
progression, gefitinib (250 mg daily) was
started as TKIs response predictors were
present (female gender, never-smoker, ad-
enocarcinoma subtype, and the presence
of L858R point mutation in EGFR gene
exon 19). This resulted in a major clinical
and radiologic response. Concurrent mac-
ulopapular erythema and follicular lesions
appeared on her face and chest and were
considered as a grade III skin toxicity.
However, thoracocentesis was performed
twice because of a symptomatic compart-
mentalized right pleural effusion. The
pleural fluid remained repeatedly aseptic.
Three months later, the patient
was hospitalized because of right rib
pain, anorexia, and vomiting. Tempera-
ture was 38.5°C. Skin examination re-
vealed persistence of EGFR-TKIs-related
lesions and parietal edema at previous
pleural puncture points. White blood cells
were 10,200/ml with 74% neutrophils and
C-reactive protein was 208 mg/l. Chest
radiograph and computed tomography
scan showed pulmonary infiltrates and
compartmentalized right pleural effusion
(Figure 1). Pleural fluid was serosanguin-
eous, pleural-to-plasma protein and LDH
ratios were 1.64 and 4.42, respectively,
and pH was 7.2. Culture grew a wild P.
acnes strain. Cytology showed infiltration
with neutrophils without tumoral cells.
Skin colonization by P. acnes was evi-
denced.
Amoxicillin plus moxifloxacin
treatment was started. A chest tube was
placed, which resulted in fever decrease
and C-reactive protein level normaliza-
tion. Because of the persistence of pleu-
ral effusion, a right thoracotomy was
performed, which confirmed pleural
space infection as brown pleural fluid
was evacuated. Gram’s stain evidenced
gram-positive bacilli. A culture did not
grow. There was no cancer identified at
the thoracotomy. After surgery, the pa-
tient improved and was back home after
a 43-day long hospitalization.
P. acnes is a normal commensal of
skin flora and has often been considered
as a contaminant of blood cultures and of
other fluids secondary to skin piercing. It
has more recently been recognized as a
potential pathogen in acnea vulgaris and in
neurosurgical and bone-joint infections.3
In this case, the mechanism of pleural
infection is not straightforward. P. acnes
is a commensal resident of lung and
lymph nodes.4 One may therefore hypo-
thetize that gefitinib induced an increase
of P. acnes inoculum in lymph nodes with
a subsequent pleural seeding. On the other
hand, pleural inoculation might have been
a consequence of repeated thoracocente-
ses. Bacterial superinfections have already
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FIGURE 1. Chest radiograph showing compartmentalized right pleural effusion
with pulmonary infiltrates and reduced right lung volume (A). Transversal (B) and
frontal (C) chest computed tomography scan slices showing voluminous and com-
partmentalized right infrapulmonary pleural effusion with mild mediastinal con-
tralateral deviation.
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been described in EGFR-TKIs treated pa-
tients, especially with Staphylococcus au-
reus nasal carriage or extensive midface
involvement.5 Inhibition of EGFR signal-
ing on epidermal and adnexal epithelium
may lead to skin barrier impairment with
increased bacterial carriage. Then, it is still
unclear if EGFR-TKIs-induced skin le-
sions increase P. acnes colonization or if
P. acnes is directly involved in skin tox-
icity as it is in acnea vulgaris. Topical and
systemic antibiotics have been used to
treat these skin lesions.2 Interestingly, tet-
racycline is used mostly for its immuno-
modulatory properties, but its antibiotic
activity against P. acnes could prevent the
risk of invasive infections. Moreover, pro-
phylactic treatment should be considered
before piercing an altered skin to decrease
bacterial carriage and therefore, the risk of
bacterial seeding.
We describe the first case of P.
acnes pleural empyema associated with
EGFR-TKIs. Increasing use of these
molecules should warn clinicians of this
rare but potentially lethal complication
especially with thoracocenteses.
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Pulmonary Epithelioid
Haemangioendothelioma
and Bevacizumab
To the Editor:
Pulmonary epithelioid hemangioen-
dothelioma (PEH) is a rare tumor of the
lung.1 Surgery is proposed in case of
unilateral nodules.2 In case of bilateral
nodules and/or pleural involvement,
several antineoplastic agents have been
used with poor beneficial effects in most
cases.3 Because PEH is a vascular tu-
mor, the use of antiangiogenic therapy
may be suggested. So, we report here the
first case, to our knowledge, of a patient
treated with bevacizumab and chemo-
therapy.
A 41-year-old man was admitted
for fever, cough, and breathlessness.
His weight had fallen by 4 kg. Chest
radiograph and thoracic computed to-
mography scan showed numerous bi-
lateral calcified nodules, condensation
in the right lower lobe, alveolar infil-
trate predominant in the left upper
lobe, and bilateral pleural effusion
(Figure 1). Positron-emission tomog-
raphy exhibited an increased uptake of
18F-fluorodeoxyglucose in the con-
densation of the right lower lobe and
pleura. Bronchoscopy with bronchoal-
veolar lavage and bronchial biopsies
were normal. Thoracocentesis revealed
bloody fluid without malignant cells.
A right thoracoscopy was performed.
Histologic examination of the pleural
and pulmonary biopsies showed simi-
lar features with monomorphic malig-
nant proliferation made up of cells
with nuclear pleomorphism and rare
atypical mitoses surrounding the ves-
sels. Staining of the tumoral tissues
was positive for antivimentin and anti-
CD34 antibodies, and negative for an-
ticytokeratin antibodies. These findings
supported the diagnosis of epithelioid
hemangioendothelioma. Expression of
vascular epithelium growth factor recep-
tor was highly positive.
The patient started chemother-
apy with cisplatin and etoposide for
one cycle. Because of progressive dis-
ease, he received interferon alpha for 1
month. However, his disease progressed
and he was started with bevacizumab
(450 mg). Thereafter, he remained sta-
ble and a combination of carboplatin-
paclitaxel with bevacizumab (15 mg/kg)
was given on day 1.
Chemotherapy was repeated every
21 days for five cycles. The patient
showed a dramatic improvement in clin-
ical status. The thoracic computed to-
mography scan revealed a good partial
response (Figure 2).
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FIGURE 1. Thoracic computed tomography scan performed before bevaci-
zumab showing bilateral pleural effusion, condensation with a small cavity in
the right-lower lobe, peripheral opacity in the middle lobe with round glass
opacities.
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